Podcasts about actinium

The mini-protein radiopharmaceutical AKY-1189, designed to deliver the alpha-emitting isotope Actinium-225 (225Ac) to tumors expressing the Nectin-4 transmembrane protein, has been found to achieve favorable dosing to tumors, while minimizing exposure to non-target tissues, including the kidney. Data on the biodistribution and tumor uptake of the drug were reported at the 2024 EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium held in Barcelona. Researcher Machaba Mike Sathekge, PhD, Professor and Head of the Department of Nuclear Medicine at the University of Pretoria and Steve Biko Academic Hospital in South Africa. He is also CEO of Nuclear Medicine Research Infrastructure and Chairman of the South African Medical Research Council.

Actinium-225 is a radioactive isotope that kills cancer cells with a burst of alpha particles, but it was difficult to make enough of it — until now. https://www.drugdiscoverynews.com/from-warhead-to-cancer-killer-the-quest-for-more-actinium-225-15934

Et ældre ægtepar er tilbage på overlægens kontor i Tyskland. Sidst de var her, fik de den frygtelige nyhed om, at manden er terminalt syg med prostatakræft. Nu er de tilbage, og denne gang er stemningen en helt anden. Overlægen tilbyder nemlig, at manden kan deltage i en række nye, kliniske forsøg, med det yderst sjældne stof: actinium-225. Og måske kan det redde hans liv.Periodisk – en RAKKERPAK original produceret af Rakkerpak Productions. Historierne du hører bygger på journalistisk research og fakta. De kan indeholde fiktive elementer som for eksempel dialog. Hvis du kan lide min fortælling, så husk at gå ind og abonnér, give en anmeldelse og fortæl dine venner om Periodisk. Podcasten er blevet til med støtte fra Novo Nordisk Fonden. Hvis du vil vide mere kan du besøge vores website periodisk.dk Afsnittet er skrevet og tilrettelagt af Nanna Ludmilla Wedel Føns  Tor Arnbjørn og Dorte Palle er producere Jens Bjørn står for lyddesign og mix Simon Bennebjerg er vært

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.'Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Sandesh Seth, the CEO and Chairman of Actinium Pharmaceuticals uses targeted radiotherapy to effectively destroy diseased bone marrow and allow new bone marrow to take over the immune functions. This approach offers a way for those currently unable to receive a transplant to have a chance for a transplant and potentially be cured of acute myeloid leukemia. Sandesh explains, "What we've shown in our Phase 3 program is we could take patients with acute myeloid leukemia, one of the deadliest cancers known to man, where drugs don't work on these patients, and they live about two to three months unless they can get a bone marrow transplant. With our lead drug, Iomab-B, we've shown that we can take non-transplantable patients because they're too weak or frail, and drugs don't work on them. And they have active disease, so they live only about three months. They can't get a transplant because they're too weak. And if you give them drugs, they may die. Or if you give them the conditioning needed to wipe out their diseased bone marrow, which is the factory from where the blood cancer spreads, they can't access the transplant."  "Iomab-B takes these non-transplant patients, it targets the disease, it kills the disease in a matter of days. It destroys the diseased bone marrow so that they can go and get a new bone marrow transplant or hemopoietic stem cells, which can then take over normal blood and immune function and restore the patient to health. It enables improved access and outcomes regarding the extension of survival and even cures in several patients, which we've shown in our Phase 3 trial. We will file licensing applications to the FDA later this year to get the drug hopefully approved next year and get it into the hands of patients." #ActiniumPharma #Radiotherapies #Radiotherapy #BloodCancer #AML #BMT #Cancer #Oncology #Hematology #BioPharma #Pharmaceuticals #OneNews #FightCancer #CancerResearch ActiniumPharma.com Download the transcript here

Sandesh Seth, the CEO and Chairman of Actinium Pharmaceuticals uses targeted radiotherapy to effectively destroy diseased bone marrow and allow new bone marrow to take over the immune functions. This approach offers a way for those currently unable to receive a transplant to have a chance for a transplant and potentially be cured of acute myeloid leukemia. Sandesh explains, "What we've shown in our Phase 3 program is we could take patients with acute myeloid leukemia, one of the deadliest cancers known to man, where drugs don't work on these patients, and they live about two to three months unless they can get a bone marrow transplant. With our lead drug, Iomab-B, we've shown that we can take non-transplantable patients because they're too weak or frail, and drugs don't work on them. And they have active disease, so they live only about three months. They can't get a transplant because they're too weak. And if you give them drugs, they may die. Or if you give them the conditioning needed to wipe out their diseased bone marrow, which is the factory from where the blood cancer spreads, they can't access the transplant."  "Iomab-B takes these non-transplant patients, it targets the disease, it kills the disease in a matter of days. It destroys the diseased bone marrow so that they can go and get a new bone marrow transplant or hemopoietic stem cells, which can then take over normal blood and immune function and restore the patient to health. It enables improved access and outcomes regarding the extension of survival and even cures in several patients, which we've shown in our Phase 3 trial. We will file licensing applications to the FDA later this year to get the drug hopefully approved next year and get it into the hands of patients." #ActiniumPharma #Radiotherapies #Radiotherapy #BloodCancer #AML #BMT #Cancer #Oncology #Hematology #BioPharma #Pharmaceuticals #OneNews #FightCancer #CancerResearch ActiniumPharma.com Listen to the podcast here

This is for hardcore PSMA aficionados!! This is the 7th of our ProsTIC/Prostate Cancer Foundation Global Webinars focussing on all things PSMA theranostics (you can find the rest in our back catalogue stretching back to April 2020). We peek into theranostics beyond what we currently have with beta-emitters like LuPSMA, into the tantalising world of alpha-PSMA theranostics. Multidisciplinary researchers from the PCF-funded TACTICAL project give a sneak into current and future work. Hear from Memorial Sloan Kettering Cancer Center experts Prof Mike Morris, Dr Lisa Bodei and Dr Jason Lewis about very exciting developments in DLL3 imaging and theranostics in neuroendocrine prostate cancer;  Dr Marwa Rahimi (Radiochemist at Peter MacCallum Cancer Centre) and David Pattison (Nuclear Medicine Physician, Royal Brisbane Hospital), overview Lead-212 targeted alpha therapy; and Dr Megan Crumbaker (Medical Oncologist (St Vincent's Hoapital, Sydney) who discusses Actinium-225 clinical data. Plus Dr James Buteau (Nuclear Medicine Physician, Peter Mac) on the Q&A Co-hosted by Declan Murphy and Michael Hofman from the GU Cast studio in Melbourne. along with Dr Howard Soule and Dr Andrea Miyahira from the PCF in California. Even better as a video podcast 

Actinium Pharmaceuticals (ATNM) is a clinical-stage biopharmaceutical company. CEO Sandesh Seth discusses ATNM which is developing a new radiotherapy candidate for cancer patients. The company released promising results from trials of its radiotherapy candidate IOMAB-B which could help patients with relapsed or refractory acute myeloid leukemia receive bone marrow transplants. He then goes over the outlook for the company. Tune in to find out more about the stock market today.

An interview with Dr. Rohan Garje from Miami Cancer Institute in Miami, FL, lead author on "Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation." Dr. Garje reviews the new evidence and the latest recommendation update for the use of 177Lu-PSMA-617, a radioligand therapy in patients with PSMA-positive mCRPC, along with it's implications for clinicians and patients. For more information, visit www.asco.org/genitourinary-cancer-guidelines.   TRANSCRIPT Brittany Harvey: Hello, and welcome to the ASCO Guidelines Podcast series, brought to you by the ASCO Podcast Network; a collection of nine programs, covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all the shows, including this one at: asco.org/podcast. My name is Brittany Harvey, and today I'm interviewing Dr. Rohan Garje from Miami Cancer Institute in Miami, Florida, lead author on, ‘Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation'. Thank you for being here, Dr. Garje. Dr. Rohan Garje: Absolutely. Thank you so much for having me, Brittany. Brittany Harvey: Great. And first, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The full Conflict of Interest information for this guideline panel is available online with the publication of the guideline in the Journal of Clinical Oncology. Dr. Garje, do you have any relevant disclosures that are directly related to this guideline topic? Dr. Rohan Garje: Yes. I have received institutional research funding from Pfizer, Amgen, Endocyte, and AAA, who have drugs for the treatment of prostate cancer. Brittany Harvey: Excellent. Thank you for those disclosures. Then getting into the content of this guideline update, what prompted this rapid update to the ‘ASCO Guideline on Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer', which was previously published in 2014? Dr. Rohan Garje: Since 2014, there have been several new drugs that have been approved for prostate cancer management. And most recently in March 2022, FDA has approved 177Lutetium-PSMA-617 for patients with PSMA scan-positive metastatic castration-resistant prostate cancer. This led to the team from ASCO to develop this new rapid recommendation update. Now, this approval actually has been based on the efficacy data published in Vision clinical trials. To give you a little background about Lutetium, it is a novel β-energy-emitting radioligand therapy. In this particular study, this agent was combined with best standard of care, and compared to best standard care alone, in men with metastatic castration-resistant prostate cancer, who had a positive PSMA scan. Briefly, the study was both clinically and statistically positive, and has shown improvement in both overall survival and radiographic progression-free survival. The median overall survival was about 15.3 months with the combination therapy, compared to 11.3 months with the standard care arm. Brittany Harvey: Great. And then based off this new evidence and the new approval from the FDA for 177 Lutetium-PSMA-617, what are the updated recommendations from the guideline panel? Dr. Rohan Garje: The panel recommends the use of 177 Lutetium-PSMA-617 as a treatment option in patients with PSMA PET/CT positive metastatic castration-resistant prostate cancer, who have been previously treated with at least one line of androgen receptor pathway inhibitor, and at least one line of prior axon-based chemotherapy. Brittany Harvey: Great. And then, what should clinicians know as they implement the use of this drug and this new recommendation by the guideline panel? Dr. Rohan Garje: A very good question. It is important to select patients based on a positive PSMA scan. That is, all the metastatic lesions should be positive on the PSMA scan, and there should not be any large lymph nodes or visceral organ metastatic disease that are PSMA negative. Additionally, physicians can use Gallium 68 PSMA-11, or F-18 Piflufolastat as radio tracers for PSMA scan to determine eligibility. Additionally, there are several other factors that need to be considered, such as: the patient should have baseline good blood counts, as well as renal function to be eligible for this therapy, as this treatment has a potential to cause mild suppression and impairment of renal function. The most common side effects associated with this drug are fatigue, dry mouth, dry eyes, and nausea. The treatment in general is for four to six cycles. Each cycle is for every six weeks. The fifth and sixth cycles should be considered only if patients are responding well to the therapy and have no significant toxicities. It is also important for the physicians to note that there are several additional treatment options for patients with metastatic castration-resistant prostate cancer, who had prior anti-androgen docetaxel therapy. They include; Cabazitaxel, PARP inhibitors for patients who have mutations in DNA repair, gene mutations such as BRCA1 and BRCA2, and immunotherapy with Pembrolizumab for patients with MSI-high status, or tumor mutation burden greater than 10. Brittany Harvey: Thank you for describing that nuance behind the recommendations. So then, in addition, how does this update impact patients with metastatic castration-resistant prostate cancer? Dr. Rohan Garje: 177 Lutetium-PSMA-617 is the first radioligand therapy approved for the treatment of prostate cancer. Previously, we had Radium-223 as a radiopharmaceutical, but this particular agent is unique in the sense, it is a radioligand therapy where it is chelated to PSMA. So, it is very targeted therapy which works for both bone and visceral organ metastasis. So, this is an exciting treatment option for patients, as it has been shown to have improvement in overall survival. This adds to the current treatment choices of anti-androgens, chemotherapy, as well as targeted therapies for prostate cancer patients. Brittany Harvey: Great. It's exciting to have a new treatment option for patients. So then finally, what are the outstanding questions regarding systemic therapy for metastatic castration-resistant prostate cancer? Dr. Rohan Garje: We are at an exciting stage in the management of prostate cancer. In the last decade, we have seen several new drugs; some are specific targeted agents, some are specific immunotherapy agents. Now, we are entering into this realm of radioligand therapy, which is very exciting. There are several other novel radioligand therapies such as; Actinium, Thorium, Lead, which are being evaluated in the treatment of prostate cancer. So, in the next several years, we will see several new drugs that have been developed. In addition, there are other agents called T-cell-engaging therapies, which are being evaluated to improve the outcomes. So, the last decade definitely has seen a lot of new improvements, but we are so excited that several new treatment choices are now available for patients, and several are in clinical evaluation. So, the future is bright for the patients with prostate cancer, where we have several new treatment choices to improve their outcomes. Brittany Harvey: It sounds like an exciting time for developments in prostate cancer. So, I want to thank you so much for your time today, Dr. Garje, and thank you for all of the work you did to update this guideline. Dr. Rohan Garje: Thank you so much. I really thank ASCO leadership and the team for giving me this opportunity, and thank you, Brittany, for hosting me on this podcast. Brittany Harvey: And thank you to all of our listeners for tuning into ASCO Guidelines Podcast series. To read the full guideline, go to: www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO guidelines app, available in iTunes or the Google Play store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe, so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement.    

Dr. Phil Kantoff is the CEO and Co-Founder and Alex Brown is the COO of Convergent Therapeutics which is developing the next generation of targeted therapies to treat cancer. Drawing on insights from developments in radiopharmaceuticals, Convergent focuses on radioantibodies that are radioisotopes attached to antibodies directed to treat prostate cancer. Phil explains, "Antibodies will recognize surface molecules on cancer cells and they can be linked to radioisotopes. We are focused on an isotope known as Actinium-225, which is an important radioisotope because it's different than isotopes that have been previously used, it's an alpha-emitting radiopharmaceutical. Alpha particles are much larger, they're much more powerful, and they travel a shorter distance. You can deliver a very powerful, very targeted therapy to cancer." "We have clinical trials that are taking place right now that are showing remarkable activity using the combination of the directed antibody against prostate cancer cells, specifically prostate-specific membrane antigen coupled to this isotope, Actinium-225." Alex continues, "Our radioantibodies, which is what we're talking about here, are novel enough that there are few if any, examples of marketed products out there. It's a field that's emerging, so aside from having the experience in antibody development and commercialization, some of this is new to our team as well as to others." @ConvergentRx @DrPhilKantoff #ProstateCancer #Radiopharmaceuticals #PSMA #Radioantibody #RadioLingandTherapy #Oncology #Biotechnology ConvergentRx.com Listen to the podcast here

Dr. Phil Kantoff is the CEO and Co-Founder and Alex Brown is the COO of Convergent Therapeutics which is developing the next generation of targeted therapies to treat cancer. Drawing on insights from developments in radiopharmaceuticals, Convergent focuses on radioantibodies that are radioisotopes attached to antibodies directed to treat prostate cancer. Phil explains, "Antibodies will recognize surface molecules on cancer cells and they can be linked to radioisotopes. We are focused on an isotope known as Actinium-225, which is an important radioisotope because it's different than isotopes that have been previously used, it's an alpha-emitting radiopharmaceutical. Alpha particles are much larger, they're much more powerful, and they travel a shorter distance. You can deliver a very powerful, very targeted therapy to cancer." "We have clinical trials that are taking place right now that are showing remarkable activity using the combination of the directed antibody against prostate cancer cells, specifically prostate-specific membrane antigen coupled to this isotope, Actinium-225." Alex continues, "Our radioantibodies, which is what we're talking about here, are novel enough that there are few if any, examples of marketed products out there. It's a field that's emerging, so aside from having the experience in antibody development and commercialization, some of this is new to our team as well as to others." @ConvergentRx @DrPhilKantoff #ProstateCancer #Radiopharmaceuticals #PSMA #Radioantibody #RadioLingandTherapy #Oncology #Biotechnology ConvergentRx.com Download the transcript here

Welcome To season 3 you chumps! hope you were safe and your holiday was relaxing, because we came to bring chaos. James and Aevry discuss the break, covid, really smart gorillas, breastmilk, and our inevitable fallout with the furry community.

We all know that radioactive rocks glow in the dark, except they actually don't, except for when they actually do.

We all know the typical advice for sleeping better: no blue light before bed, less coffee, take melatonin, etc. But out of the dozens of things you hear about, what actually matters? And what about the things we don't talk about, like the monsters that rise up out of your subconscious as you lie in bed at night? 0:00 Actinium's Question 0:55 Mike's Sleep Schedule 4:23 Dan's Sleep Schedule 7:36 What Do You Do to Help Yourself Go to Sleep? 9:52 What Keeps You Up At Night? Adenosine, Circadian Rhythm 18:46 Lighting 24:00 Quick Note on Melatonin 25:00 Brain State on Falling Asleep and the Guy With a Gun Coming to Get You 26:56 The Sunny Island, The Rising Water, And The Monsters From The Deepest Depths of Your Subconscious 39:45 Summarizing Join our DISCORD: https://discord.gg/tfvVUxk45M --- Support this podcast: https://anchor.fm/the-overanalyzers/support

Apa sih musik HIPROCK ? nah Kali ini kita ada ACTINIUM Yang Bakal Ngobrol Seputaran, HIPROCK... Djangan Gak Di simak yah...

Actinium Pharma (#ATNM) is commercializing Antibody-Radiation Conjugates (ARC) for the treatment of diseases that require conditioning regimens (Bone Marrow Transplant, Stem Cell Transplant, Adoptive Cell Therapies). The current state of total body irradiation leaves patients with significant side effects and excludes a large demographic due to potential lethality of the conditioning treatment. ATNM is testing a targeted approach that could allow for substantially more patients to be treated and reduce side effects. I go through the details of the company and talk about why the risk/reward favors longs into the next catalyst. Karyopharm (#KPTI) recently received news that their drug Selinexor (XPOVIO) is approved for 3L DLBCL, which should drive a nice amount of revenue for the company. Link to myeloablative therapy costs: https://www.pharllc.com/wp-content/uploads/2017/11/10-2017_Cost.pdf If you want to help the show, you can donate here: https://tips.pinecast.com/jar/breaking-biotech You can also open an account at Tastyworks using my referral code: https://start.tastyworks.com/#/login?referralCode=ZWQ77XG2PZ Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

Back On The Beat - October 26, 2019 See omnystudio.com/listener for privacy information.

In this episode, we discuss: (1) How Rose became interested in radioisotopes from an early interest in chemistry and medicine (2) What an isotope is and how Actinium-225 is created (3) Why the demand for Actinium-225 is increasing and the challenges the Tri-Lab Project faces in meeting this demand (4) The role of education in radiation acceptance

For our 99th episode, you can count on Julia to describe the origins of every single element name on the periodic table. We’ve got you covered from Actinium to Zirconium! Later, enjoy a quiz called “Title Elements”! . . . [Music: 1) Tom Lehrer, “The Elements,” Music by Sir Arthur Sullivan, 1959; 2) Frau Holle, “Ascending Souls,” 2017. Courtesy of Frau Holle, CC BY-NC 3.0 license.]

Professor Allan Blackman from AUT explores the chemical elements actinium and americium, and the Kakapo Files podcast catches up with the work of the island rangers.

Professor Allan Blackman from AUT explores the chemical elements actinium and americium, and the Kakapo Files podcast catches up with the work of the island rangers.

The first alphabetical element in the periodic table is actinium. It is a heavy radioactive element, as we discover in episode 1 of Elemental, with Professor Allan Blackman from AUT.

The first alphabetical element in the periodic table is actinium. It is a heavy radioactive element, as we discover in episode 1 of Elemental, with Professor Allan Blackman from AUT.

The first alphabetical element in the periodic table is actinium. It is a heavy radioactive element, as we discover in episode 1 of Elemental, with Professor Allan Blackman from AUT.

Pour ce podcast #28, nous recevions le patron d'actinium, Michael Bechler tout juste descendu de l'avion qui le ramenait du Quebec. Cerise sur le gâteau, ce numéro 28 marquait également le retour d'Antistress, notre kro-niqueur à mi-temps. Au programme de la news, du wazzuf et LTP nous parle de la balise vidéo.

Pour ce podcast #28, nous recevions le patron d'actinium, Michael Bechler tout juste descendu de l'avion qui le ramenait du Quebec. Cerise sur le gâteau, ce numéro 28 marquait également le retour d'Antistress, notre kro-niqueur à mi-temps. Au programme de la news, du wazzuf et LTP nous parle de la balise vidéo.

Actinium podcast from Chemistry World - the magazine of the Royal Society of Chemistry.

Special BBC2 Edition The Show Notes:     Geo's explanation of this week's show Intro An erotic reading in the city Unsexy…unsexy…unsexy Finally…John's great story Circumcision inquiry Occasional Songs for the Periodic Table Thulium, Ytterbium, Lutetium, Halfnium, Tantalum, Tungsten, Rhenium, Osmium, Iridium, Platinum, Gold, Mercury, Thallium, Lead, Bismuth, Polonium, Astatine, Radon, Francium, Radium, Actinium, Thorium, Protactinium Louis Pierre Monchant’s Bastardes Indestructable - Herbert "The Cat" Noble Ask George - christians and global warming (from Jay Parlar) Religious Moron of the Week - Reverend Charles Eugene Flowers Another Geologic Podcast Giveaway - translate Tantalum and win Show Close ...................................... Mentioned in the show: the Skepdudes calendar via Skepchick And as always: George's blog, website, flickr, and myspace page. Have a comment on the show, a topic for Minoishe Interroberg, or a question for Ask George? Drop George a line at geo@geologicrecords.net or through his blog. First commenter to translate the lyrics to Tantalum wins a Skepdude calendar!